Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | SCN4A | P35499 | 1/20 | 0.40 |
| ▸ | CTSC | P53634 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28789391 | 1.00 | ELANE (0.48) | ELANECYP3A4CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL21385077 | 0.98 | ELANE (0.47) | ELANECYP3A4CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL28850249 | 0.86 | F2 (0.52) | ELANECYP3A4CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL9807318 | 0.85 | ELANE (0.46) | ELANECYP3A4CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL21646169 | 0.83 | ALDH1A1 (0.47) | CYP2D6CYP1A2CYP2C19CHRNA7LMNA | |
| SCHEMBL10903756 | 0.82 | DPP4 (0.47) | ELANEDPP4CHRNA7 | |
| SCHEMBL27129010 | 0.82 | ALDH1A1 (0.44) | ELANECYP3A4CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL8691039 | 0.82 | CTSC (0.45) | DPP4CTSC | |
| SCHEMBL27125986 | 0.82 | ALDH1A1 (0.44) | ELANECYP3A4CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL11153901 | 0.80 | KMT2A (0.47) | ELANECYP3A4CYP2D6CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287129-A1 | DECARBOXYLATIVE CONJUGATE ADDITIONS AND APPLICATIONS THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY | 2024-08-29 | — | — | US | disclosed |
| US-11981704-B2 | Decarboxylative conjugate additions and applications thereof | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2024-05-14 | — | — | US | disclosed |
| CN-117377668-A | Inhalant formulations of PGDH inhibitors and methods of use thereof | 迈欧伏特治疗公司 | 2024-01-09 | — | — | CN | disclosed |
| CN-114778743-B | Detection method of trace chiral isomer D-proline in L-proline | 常州制药厂有限公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-114778743-A | Method for detecting trace chiral isomer D-proline in L-proline | 常州制药厂有限公司 | 2022-07-22 | — | — | CN | disclosed |
| US-20220002342-A1 | DECARBOXYLATIVE CONJUGATE ADDITIONS AND APPLICATIONS THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY | 2022-01-06 | — | — | US | disclosed |
| US-11136349-B2 | Decarboxylative conjugate additions and applications thereof | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2021-10-05 | — | — | US | disclosed |
| CN-110139856-A | The double inhibitor of VISTA and PD-1 access | 奥列基因发现技术有限公司 | 2019-08-16 | — | — | CN | disclosed |
| CN-106795135-B | Synthesis of isoflavanes and intermediates thereof | 系统生物股份有限公司 | 2019-08-09 | — | — | CN | disclosed |
| CN-110078743-A | Novel imidazoles-acyclic derivatives as modulators of kinase activity | 默克专利有限公司 | 2019-08-02 | — | — | CN | disclosed |
| EP-1883402-A2 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | Astex Therapeutics Limited (GB) | 2008-02-06 | — | — | EP | disclosed |
| EP-1877379-A1 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | Astex Therapeutics Limited (GB) | 2008-01-16 | — | — | EP | disclosed |
| US-20070276026-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-29 | — | — | US | disclosed |
| US-20070259886-A1 | (2,4-Dihydroxy-5-isopropyl-phenyl)-[5-(2-dimethylamino-ethoxy)-1,3-dihydro-isoindol-2-yl]-methanone; inhibits or modulates activity of heat shock protein Hsp90; useful for treating cancer, particularly hematopoietic tumors of lymphoid or myeloid lineage, prostate, lung, breast cancer, melanoma | ASTEX THERAPEUTICS, LTD. (GB) | 2007-11-08 | — | — | US | disclosed |
| US-20070259871-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | US | disclosed |
| WO-2006109075-A2 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006109085-A1 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
| EP-0486386-B1 | Novel derivatives of N-benzoylproline, process for their preparation and drugs containing them | ADIR (FR) | 1996-07-17 | — | — | EP | disclosed |
| EP-0486386-A2 | Novel derivatives of N-benzoylproline, process for their preparation and drugs containing them | ADIR ET COMPAGNIE (FR) | 1992-05-20 | — | — | EP | disclosed |
| US-4308202-A | Prolylphenylalanylarginine derivatives, process for producing same and method for measuring activity of enzymes using same | TORII & CO., LTD. (JP) | 1981-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276026-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | HSP90AB1, HSP90AB2P, HSP90AA1 | ELANE 4174/4885CYP3A4 917/4885CYP2D6 108/4885 |
| US-20070259886-A1 | (2,4-Dihydroxy-5-isopropyl-phenyl)-[5-(2-dimethylamino-ethoxy)-1,3-dihydro-isoindol-2-yl]-methanone; inhibits or modulates activity of heat shock protein Hsp90; useful for treating cancer, particularly hematopoietic tumors of lymphoid or myeloid lineage, prostate, lung, breast cancer, melanoma | HSP90AB2P, HSP90AA1, HSP90AB1 | ELANE 1225/4885CYP3A4 2059/4885CYP2D6 532/4885 |
| US-20220002342-A1 | DECARBOXYLATIVE CONJUGATE ADDITIONS AND APPLICATIONS THEREOF | PTMS, DNPEP, QPCT | ELANE 1358/4885CYP3A4 2955/4885CYP2D6 2964/4885 |
| US-20070259871-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | HSP90AB1, HSP90AB2P, HSP90AA1 | ELANE 4191/4885CYP3A4 912/4885CYP2D6 108/4885 |
| US-20240287129-A1 | DECARBOXYLATIVE CONJUGATE ADDITIONS AND APPLICATIONS THEREOF | PTMS, DNPEP, QPCT | ELANE 1358/4885CYP3A4 2955/4885CYP2D6 2964/4885 |
| US-11981704-B2 | Decarboxylative conjugate additions and applications thereof | PTMS, DNPEP, QPCT | ELANE 1358/4885CYP3A4 2955/4885CYP2D6 2964/4885 |
| US-11136349-B2 | Decarboxylative conjugate additions and applications thereof | PTMS, DNPEP, QPCT | ELANE 1358/4885CYP3A4 2955/4885CYP2D6 2964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.